🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Pergolide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    1 trial

  2. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  3. Phenazopyridine Hydrochloride

    Amneal Pharma Europe Ltd

    Pain

    phase 3 small molecule completed

    1 trial

  4. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  5. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  6. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  7. Picosulfate sodium, magnesium oxide, citric acid

    Universal Integrated

    Bowel Preparation Before Colonoscopy

    phase 3 small molecule completed

    1 trial

  8. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

  9. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  10. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  11. Pioglitazone and Glimepiride

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  12. Pioglitazone, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, GLIMEPIRIDE, GLICLAZIDE, METFORMIN HYDROCHLORIDE, GLIPIZIDE, METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN, GLIQUIDONE, Placebo for Actos 15 mg tablets, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

    Celltrion Healthcare Australia Pty Ltd

    Type 2 diabetes mellitus (T2DM)

    phase 3 small molecule active

    1 trial

  13. Pitolisant

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial

  14. Pitolisant tablet

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial

  15. Placebo

    Matinas BioPharma Holdings

    Severe Hypertriglyceridemia

    phase 3 small molecule terminated

    1 trial

  16. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Erectile Dysfunction

    phase 3 small molecule completed

    1 trial

  17. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  18. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  19. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  20. Placebo

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  21. Placebo

    Takeda

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  22. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  23. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Schizoaffective Disorder

    phase 3 small molecule completed

    1 trial

  24. Placebo

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources